EGFR and colorectal carcinoma: It is therefore reasonable to conclude that c-MET/EGFR are important biomarker signatures of tumorigenesis, tumor immune invasion, and poor prognoses, and thus can serve as attractive targets for the development of immune/chemotherapeutic strategies against CRC.